Menu

UK to Legalize Medicinal Cannabis

Patients will be able to access the drug with a prescription, and there are no plans to allow for recreational use.

Jul 27, 2018
Catherine Offord

Doctors in the UK will be able to prescribe medicinal cannabis to patients starting in the fall of this year, according to a government announcement made yesterday (July 26). The move follows national debate over high-profile cases in which children with severe epilepsy were first denied, then allowed access to cannabis oil shown to ease the symptoms of the condition.

“Recent cases involving sick children made it clear to me that our position on cannabis-related medicinal products was not satisfactory,” Interior Minister Sajid Javid told reporters yesterday, according to Reuters. “Following advice from two sets of independent advisers, I have taken the decision to reschedule cannabis-derived medicinal products—meaning they will be available on prescription.”

Until now, cannabis has been considered a Schedule 1 substance, a legal classification that means the plant can be used by researchers with a license, but is not thought to have any therapeutic value. Yesterday’s announcement indicates that cannabis-derived products intended for medicinal use will now be classified as Schedule 2, allowing them to be prescribed directly to patients by specialist physicians.

See “Marijuana Research Still Stymied by Federal Laws

Before autumn, the government will clarify which types of products will meet the definition of medicinal. In the interim, “clinicians may still apply to the Home Office Expert Panel should they wish to use a cannabis-based medicine in the treatment of a patient,” a Home Office spokesperson told reporters, according to BBC News.

Karen Gray, a woman whose child suffers from epilepsy and who has campaigned for the legalization of cannabis for medicinal use, tells The Independent that the decision is a victory for those seeking treatment. “It’s really going to help children out there, so it’s brilliant news,” she says. “There are lots of kids out there who aren’t getting this help and hopefully now they will.”

Mike Barnes, a physician at neurological rehabilitation specialist Christchurch Group who secured access to cannabis oil for a child with epilepsy earlier this year, tells The Guardian that he hopes the rules won’t be “too restrictive, but sensibly open up the way to make good quality, safe cannabis available on prescription.”

Other countries that have already allowed medical marijuana include Australia, Germany, and Peru, along with some states in the US. Recreational use is currently fully legalized in Uruguay and, as of this June, Canada.

See “Canada Could Come to the Fore in Cannabis Research

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.